by Raynovich Rod | May 30, 2012 | BIOgraph, Macro
Look for biotechnology intermediate top as we approach ASCO next week. Market is now driven by hedgies and big funds.IBB ($123.90) double top with YTD high of $126.90 Mid cap biotech index off 1.7%. DX and tools also very weak. S&P unchanged from one year...
by Raynovich Rod | May 24, 2012 | BIOgraph, Clinical Diagnostics and Tools
There were some excellent small cap companies presenting at the B. Riley Investor Conference in Santa Monica this week. Five tracks covered companies in healthcare, technology and energy, consumer/telecom, software and services and internet and media. Our focus within...
by Raynovich Rod | May 17, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850, we see a lot of countertrends like gold up $39.70 off recent lows to...
by Raynovich Rod | May 16, 2012 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Life Science ETF's and Mutual Funds
Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief...
by Raynovich Rod | May 15, 2012 | Clinical Diagnostics and Tools
Biomarker MicroCap Face-Off: BGMD vs VRML Vermillion announced Q1 Results today today with OVA1 revenues of $312K of which $114 k was licensing revenues from their testing partner Quest Diagnostics Inc.(DGX $57). Operating expenses were down to $2.4M compared to$4.8M...
by Raynovich Rod | May 10, 2012 | Clinical Diagnostics and Tools
More Bad News on Alere The second shoe has dropped on Alere (ALR $19) with the stock off 15% as the FDA inspection news regarding manufacturing and quality at the “Biosite”facility.Leerink Swann downgraded the stock to “Market Perform” after...
by Raynovich Rod | May 9, 2012 | 2024-25 Life Science Portfolios, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has...
by Raynovich Rod | May 4, 2012 | BIOgraph, Biopharmaceuticals, Macro
The NASDAQ Biotechnology Index IBB ($122.30) is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this...
by Raynovich Rod | May 3, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Clinical Diagnostics and Tools
ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an...
